ISR - IsoRay EPS misses by $0.01 beats on revenue

IsoRay (NYSE:ISR): FQ1 GAAP EPS of -$0.02 misses by $0.01. Revenue of $2.56M (+7.6% Y/Y) beats by $0.06M. Press Release Isoray CEO Lori Woods said, “We are encouraged by the prospects for our core prostate brachytherapy business which grew year over year again this quarter. As our innovation pipeline continues to evolve, we are taking what we believe are important steps critical to support the scaling of the organization in anticipation of future growth in our core prostate brachytherapy market as well as in markets related to hard-to-treat cancers.”

For further details see:

IsoRay EPS misses by $0.01, beats on revenue